Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Jose Miguel Mateos Perez, Carlos Fernandez de Larrea, José Tomás Ortiz, Luis Fernando Quintana, Joaquim Casals, Adriana Patricia Garcia, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Marta Farrero, Joan Batista Blade Creixenti, Laura Rosiñol Dachs, Maria Teresa Cibeira López

Blood (2025) 146 (Supplement 1): 7494.

https://doi.org/10.1182/blood-2025-7494

Published: 2025

Journal Articles

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Blood (2025) 146 (Supplement 1): 919.

https://doi.org/10.1182/blood-2025-919

Published: 2025

Journal Articles

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Marta Lasa, Esperanza Martin-Sanchez, Aintzane Zabaleta, Diego Alignani, Carmen Gonzalez, Noemi Puig, Elena Alejo, Jorge Labrador, Maria Casanova Espinosa, Laura Rosiñol Dachs, Sebastián Garzón, Enrique Ocio, Albert Pérez-Montaña, Irene Romera, Carmen Couto, Sunil Lakhwani, Felipe Prosper, Adrian Alegre, Elena Cabezudo, Itziar Carro, Cristina Motlló, Montserrat Cortes, Isabel Maria Garcia Cabrera, Marta Romera, Javier de la Rubia, Andrea Manubens, Alexia Suarez Cabrera, Fernando Escalante Barrigón, Carlos Aguilar-Franco, Raquel Del Campo, Maria Esther Clavero Sanchez, Joaquin Martinez-Lopez, Valentin Cabanas Perianes, María-Jesús Blanchard, Ana Lopez-Guia, Diana Sanchez Arguello, Albert Oriol, Marta Reinoso -Segura, María Lourdes Amador Barciela, Celina Benavente Cuesta, Jose Maria Arguiñano PEREZ, Beatriz Ordoñez, Francisco Taboada, Joan Batista Blade Creixenti, María-Victoria Mateos, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, Bruno Paiva

Blood (2025) 146 (Supplement 1): 578.

https://doi.org/10.1182/blood-2025-578

Published: 2025

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 250.

https://doi.org/10.1182/blood-2025-250

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2025-4042

Published: 2025

Journal Articles

Integrative omics analysis of TP53 in multiple myeloma patients

Cristina De Ramón Sánchez, Elizabeta A Rojas, Irena Misieweicz, Maria García-Alvarez, Myriam Cuadrado, Sara Cristobal, Ignacio J Cardona-Benavides, Isabel M Isidro, Maria Calasanz, Miguel Alcoceba, Ramon Garcia-Sanz, Laura Rosiñol Dachs, Joaquin Martinez-Lopez, Joan Batista Blade Creixenti, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, María-Victoria Mateos, Luis Antonio Corchete Sanchez, Norma Gutiérrez

Blood (2025) 146 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2025-2162

Published: 2025

Journal Articles

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Blood (2025) 146 (Supplement 1): 698.

https://doi.org/10.1182/blood-2025-698

Published: 2025

Journal Articles

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Jose Miguel Mateos Perez, Francesc Fernández-Avilés, Maria Teresa Cibeira López, Maria Carmen Martinez Munoz, Carlos Fernandez de Larrea, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Maria Suarez-Lledo, Maria Queralt Salas Gay, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Montserrat Rovira, Joan Batista Blade Creixenti, Laura Rosiñol Dachs

Blood (2025) 146 (Supplement 1): 5776.

https://doi.org/10.1182/blood-2025-5776

Published: 2025

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Blood (2024) 144 (Supplement 1): 7039.

https://doi.org/10.1182/blood-2024-210376

Published: 2024

Journal Articles

ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Blood (2024) 144 (Supplement 1): 496.

https://doi.org/10.1182/blood-2024-205083

Published: 2024

Journal Articles

Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades

Luis Gerardo Rodríguez-Lobato, Anna De Daniel, Arturo Pereira, Carlos Fernández de Larrea, Natalia Tovar, M Teresa Cibeira López, David F. Moreno, José Miguel Mateos Pérez, Joan Bladé, Laura Rosinol Dachs

Blood (2024) 144 (Supplement 1): 3321.

https://doi.org/10.1182/blood-2024-202549

Published: 2024

Journal Articles

Outcomes of 9/10 Mmud Allo-HCT Using Ptcy-TK Prophylaxis. Results from a Single Institution

Filipe Pinto, Alexandra Pedraza, Maria Suarez-Lledo, Laia Guardia, Paola Charry, Joan Cid, Miquel Lozano, Gerard Corrius, Noemí De Llobet, Enric Carreras, Laura Rosiñol Dachs, Francesc Fernández-Avilés, Montserrat Rovira, Carmen Martinez, Maria Queralt Salas, Jordi Esteve Reyner

Blood (2024) 144 (Supplement 1): 7342.

https://doi.org/10.1182/blood-2024-207563

Published: 2024

Journal Articles

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Blood (2024) 144 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2024-207118

Published: 2024

Journal Articles

Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Blood (2024) 144 (Supplement 1): 489.

https://doi.org/10.1182/blood-2024-210198

Published: 2024

Journal Articles

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

Blood (2024) 144 (Supplement 1): 787.

https://doi.org/10.1182/blood-2024-204867

Published: 2024

Journal Articles

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Blood (2024) 144 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2024-211383

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Integrative omics analysis of TP53 in multiple myeloma patients

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades

Outcomes of 9/10 Mmud Allo-HCT Using Ptcy-TK Prophylaxis. Results from a Single Institution

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only